Press Releases

Intensity Therapeutics to Participate in East/West CEO Conference

Jan 29 2020

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that Lewis H. Bender, President and CEO, will be a featured panelist on the “Developments in The Oncology Landscape” panel at East/West CEO. The conference will take place January 11-12,… Read more »

Data from Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients with Advanced Solid Tumors

Nov 29 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced new preliminary data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate. These data will be presented on Saturday, November 9, in an oral podium… Read more »

Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®

Oct 29 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy. The combination is being… Read more »

View All Press Releases

Publications/Papers/Posters

OncoImmunology July 16, 2019 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Article published on-line July 16, 2019 in the journal OncoImmunology.  https://doi.org/10.1080/2162402X.2019.1625687 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. ABSTRACT The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a… Read more »

ASCO 2019 Poster Presentation – Abstract 2602

Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation  

SITC 2018 Poster Presentation P622

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

View All Publications/Papers/Posters